Drug Trial Radar · NCT02223897
Mesenchymal Stem Cells Transplantation for Ischemic-type Biliary Lesions
Last checked: Nov 19, 2026Latest source record: Aug 22, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
66
Planned (sponsor's estimate)
Start
Jul 2014
Primary completion
Jun 2017
Study completion Jun 2018
Sponsor
- Lead sponsor
- Yang YangAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 22, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ischemic-type biliary lesions (ITBLs) are a major cause of graft loss and mortality after orthotopic liver transplantation (OLT). For now, there are still lacking effective treatment for ITBLs. The purpose of this study is to confirm whether human umbilical cord mesenchymal stem cells are effective in the treatment,or prevention of Ischemic-type Biliary Lesions after liver transplantation.
Conditions
- Ischemic-type Biliary Lesions
Interventions
huc-MSCsDrug
Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.
PlaceboDrug
Received conventional treatment and 50 ml saline solution once per week for the first month and once per month for 6 months(9 times in total).
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of ITBLsTime frame: 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Third Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.